ChristineHwayongChungMD

PubMed

• Advanced Human Papillomavirus-Negative Head and Neck Squamous Cell Carcinoma: Unmet Need and Emerging Therapies.
  Robin Park, Christine H Chung
  Molecular Cancer Therapeutics. 2024-12-03
• Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis.
  Nabil F Saba, Ritu Chaudhary, Kedar Kirtane, Angelo Marra, Asari Ekpenyong
  Clinical Cancer Research. 2024-10-15
• Spatial interactions modulate tumor growth and immune infiltration.
  Sadegh Marzban, Sonal Srivastava, Sharon Kartika, Rafael Bravo, Rachel Safriel
  NPJ Systems Biology and Applications. 2024-09-30

Journal Articles

• Integrated Time Course Omics Analysis Distinguishes Immediate Therapeutic Response from Acquired Resistance  
  Joseph A Califano, Christine H Chung, BioMed Central
• A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reaction  
  Maier S, Chung CH, Morse M, Platts-Mills T, Townes L, Mukhopadhyay P, Bhagavatheeswaran P, Racenberg J, Trifan OC, Cancer Medicine, 1/1/2015
• Cleaved NOTCH1 expression pattern in head and neck squamous cell carcinoma is associated with NOTCH1 mutation, HPV status and high-risk clinical features  
  Rettig EM, Chung CH, Bishop JA, Howard JD, Sharma RB, Li RJ, Douville C, Karchin R, Izumchenko E, Sidransky D, Koch W, Califano J, Agrawal N, Fakhry C, Cancer Prev Res, 1/1/2015
• A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma  
  Gilbert J, Schell MJ, Zhao X, Murphy B, Tanvetyanon T, Leon ME, Hayes DN, Haigentz M, Saba N, Nieva J, Bishop J, Sidransky D, Ravi R, Bedi A, Chung CH, Oral Oncol, 1/1/2015
• Novel targets in head and neck cancer: Should we be optimistic?  
  Krigsfeld G, Chung CH, Clin Can Res, 1/1/2015
• Prognostic implication of persistent human papillomavirus type 16 DNA detection in oral rinses for human papillomavirus- related oropharyngeal carcinoma  
  Rettig EM, Wentz A, Posner MR, Gross ND, Haddad RI, Gillison M, Fakhry C, Quon H, Sikora AG, Stott WJ, Lorch JH, Gourin CG, Quo Y, Xiao W, Miles BA, Richmon JD, Anders..., JAMA Oncol, 1/1/2015
• Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing  
  Chung CH, Guthrie VB, Masica DL, Tokheim C, Kang H, Richmon J, Agrawal, N, Fakhry C, Quon H, Subramaniam RM, Zuo Z, Seiwert T, Chalmers ZR, Frampton GM, Ali SM, Yelens..., Ann Oncol, 1/1/2015
• Surgical salvage improves overall survival for HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer  
  Guo T, Qualliotine JR, Ha PK, Califano JA, Kim Y, Saunders JR, Blanco R, D'Souza G, Zhang Z, Chung CH, Kiess A, Gourin CG, Koch W, Richmon JD, Agrawal N, Eisele DW, Fa..., Cancer, 1/1/2015
• Detection of somatic mutations and HPV in the saliva and blood of patients with head and neck squamous cell carcinomas  
  Wang Y, Sidransky D, Papadopoulos N, Kiess A, Diaz L, Bettegowda C, Myers J, Westra W, Koch W, Califano J, Kinzler K, Sausen M, Pickering C, Fakhry C, Springer S, Mulv..., Sci Transl Med, 1/1/2015
• Predicting survival in head and neck squamous-cell carcinoma from TP53 mutation  
  Masica DL, Li S, Douville C, Manola J, Ferris RL, Burtness B, Forastiere AA, Koch WM, Chung CH, Karchin R, Hum Genet, 1/1/2015
• Diagnostic accuracy of follow-up FDG PET or PET/CT in patients with head and neck cancer after definitive treatment: A systematic review and meta-analysis  
  Sheikhbahaei S, Taghipour M, Ahmad R, Fakhry C, Kiess AP, Chung CH, Subramaniam RM, AJR Am J Roentgenol, 1/1/2015
• p16 protein expression and human papillomavirus status as prognostic biomarkers of non-oropharyngeal head and neck squamous cell carcinoma  
  Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, Wang D, Redmond KP, Shenouda G, Trotti A, Raben D, Gillison ML, Jordan RC, Le QT, J Clin Oncol, 1/1/2014
• CHK it out! Blocking WEE kinase routs TP53 mutant cancer  
  Bauman JE, Chung CH, Clin Can Res, 1/1/2014
• A Randomized Phase III Trial to Test Accelerated versus Standard Fractionation in Combination with Concurrent Cisplatin for Head and Neck Carcinomas (RTOG0129): Long T...  
  Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway T, Fortin A, Gore E, Westra WH, Chung CH, Jordan RC, Gilliso..., J Clin Oncol, 1/1/2014
• NOTCH pathway activation in head and neck cancer  
  Sun W, Gaykalova DA, Ochs MF, Mambo E, Arnaoutakis D, Liu Y, Loyo M, Agrawal N, Howard J, Li R, Ahn S, Fertig E, Sidransky D, Houghton J, Buddavarapu K, Sanford T, Cho..., Cancer Res, 1/1/2014
• Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously trea...  
  Maitland ML, Levine MR, Lacouture ME, Wroblewski KE, Chung CH, Gordon IO, Szeto L, Ratko G, Soltani K, Kozloff MF, Hoffman PC, Salgia R, Carbone DP, Karrison TG, Vokes EE, BMC Cancer, 1/1/2014
• RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2  
  Sun M, Gomes S, Chen P, Frankenberger CA, Sankarashararma D, Chung CH, Chada KK, Rosner MR, Oncogene, 1/1/2014
• Using a question-prompt list as a communication aid in advanced cancer care  
  Yeh JC, Cheng MJ, Chung CH, Smith TJ, J Oncol Practice, 1/1/2014
• Loss of HNF6 expression correlates with human pancreatic cancer progression  
  Pekala K, Ma X, Kropp P, Petersen C, Hudgens C, Chung CH, Shi C, Merchant N, Maitra A, Means A, Gannon MA, Lab Invest, 1/1/2014
• A 3'UTR KRAS variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma  
  Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastie..., Ann Oncol, 1/1/2014
• Prognostic value of FDG PET metabolic tumor volume in human papillomavirus- positive stage III and IV oropharyngeal squamous cell carcinoma  
  Alluri K, Tahari AK, Wahl RL, Koch W, Chung CH, Subramaniam RM, AJR Am J Roentgenol, 1/1/2014
• Clinical genomic and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke  
  Li R, Faden DL, Fakhry C, Langelier C, Jiao Y, Wang Y, Wilkerson MD, Pedamallu CS, Old M, Lang J, Loyo M, Ahn SM, Tan M, Gooi Z, Chan J, Richmon J, Wood LD, Hruban RH,..., Head Neck, 1/1/2014
• Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC  
  Zhang KH, Jones L, Lim S, Maher CA, Adkins D, Lewis J, Kimple RJ, Fertig EJ, Chung CH, Herrlich A, Ellis MJ, Van Tine B, Michel LS, Oncotarget, 1/1/2014
• Opportunities and challenges in the era of molecularly targeted agents and radiation therapy  
  Lin SH, George TJ, Ben-Josef E, Bradley J, Choe K, Edelman MJ, Guha C, Krishnan S, Lawrence TS, Le QT, Lu B, Mehta M, Peereboom D, Sarkaria J, Seong J, Wang D, Wellive..., J Natl Cancer Inst, 1/1/2013
• Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment  
  Lucs A, Saltman B, Chung CH, Steinberg B, Schwartz DL, Head Neck, 1/1/2013
• Join now to see all

Books/Book Chapters

• Molecular Targets of Head and Neck Cancer. Current Cancer Research 
  Chapter: Chapter 7-The PI3K signaling pathway in head and neck squamous cell carcinoma. 
  Page 131 - 161Howard J, Chung CHSpringer, New York, NY2014
• Head and Neck Cancer: A Multidisciplinary Approach 
  Chapter: Chapter 16: Cancer of the Oral Cavity: General Principles and Management. 
  Koch WM, Stafford E, Chung CH, Quon HWolters Kluwer Health--Lippincott Williams & Wilkins2014
• Textbook of Uncommon Cancer 
  Chapter: Chapter 9: Esthesioneuroblastoma. 
  Page 133 - 142Murphy BA, Aulino JM, Chung CH, Ely K, Sinard R, Cmelak AJohn Wiley & Sons, Ltd.Edition 3rd,2006

Lectures

• Ready for a Molecular Signature as a Prognostic/Predictive Biomarker? 
  Milan, Italy - 1/24/2014
• What is the current and future role of systemic therapy in the TOS-treated patients? 
  Baltimore, MD - 1/24/2014
• Benefits of genomic medicine: what to tell the patient. 
  Boston, MA - 1/14/2014
• Integrating anti-PD1/PDL1 inhibitors into the management of head and neck cancer. 
  Mount Laurel, NJ - 1/10/2014
• Are we ready for biomarker-driven clinical trials in head and neck cancer? 
  Bethesda, MD - 1/3/2014
• HPV-positive head and neck cancer and its genomic profile. 
  Baltimore, MD - 1/1/2014
• Ethical considerations for genomics in cancer care and research: science, technology, and research perspective. 
  Chicago, IL - 1/31/2013
• Do EGFR inhibitors work in patients with HPV-positive HNSCC? 
  National Harbor, MD - 1/25/2013
• Reaping the benefits from the genomic data in head and neck cancer. 
  Johns Hopkins University, Baltimore, MD - 1/23/2013
• Personalized therapy for head and neck cancer: present and future. 
  Medical University of South Carolina, Charleston, SC - 1/18/2013
• Genomics and proteomics technology in biomarker discovery: Matching the phenotype and -omics data. 
  Atlanta, GA - 1/18/2013
• Biology of HPV-related head and neck cancer. 
  Johns Hopkins University, Baltimore, MD - 1/15/2013
• p16 expression as a human papillomavirus (HPV)-independent prognostic biomarker of non-oropharyngeal squamous cell carcinoma (non-OPSCC). 
  Philadelphia, PA - 1/15/2013
• Recent updates in the Management of Head and Neck Cancer 
  Johns Hopkins University - 1/14/2013
• Phase II randomized trial of the combination of cetuximab and sorafenib or single agent cetuximab in patients with refractory, recurrent and/or metastatic squamous cel... 
  Bethesda, MD - 1/9/2013
• Targetable genetic alterations in head and neck cancer. 
  Atlanta, GA - 1/7/2013
• Advancing the therapeutic ratio in head and neck cancer: Benchtop to clinical advances. 
  Greater Baltimore Medical Center, Baltimore, MD - 1/6/2013
• Reaping the benefits of the genomic report: What to tell the patient. 
  Chicago, IL - 1/3/2013
• Targetable Genetic Alterations in SCCHN 
  Phoenix, AZ - 1/27/2012
• Chemotherapy in HNSCC 
  Johns Hopkins University - 1/21/2012
• The Management of Head and Neck Cancer 
  Johns Hopkins University - 1/19/2012
• EGFR inhibitor therapies in head and neck cancer. 
  Johns Hopkins University, Baltimore, MD - 1/14/2012
• Novel treatment approaches to HPV-related head and neck cancer. 
  Baltimore, MD - 1/13/2012
• New treatment options for head and neck cancer. 
  New York, NY - 1/11/2012
• Personalized Therapy for Head and Neck Cancer: Present and Future 
  Feinstein Institute for Medical Research, Manhasset, NY - 1/7/2012
• Join now to see all

Other

• Supportive care for patients with head and neck cancer. Medscape Hematology-Oncology. 
  Murphy BA, Chung CH, Medscape, LLC
  1/1/2006